Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer

Gynecologic Oncology

Volumn 93, Issue 2, 2004, Pages 390-393

  Markman, Maurie ^a   Webster, Kenneth ^b   Zanotti, Kristine ^b   Rohl, Jacqueline ^b   Belinson, Jerome ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

Chemotherapy; Ovarian cancer; Tamoxifen

Indexed keywords

CA 125 ANTIGEN; TAMOXIFEN;

CANCER CENTER; CANCER GROWTH; CANCER RECURRENCE; CANCER SIZE; HUMAN; MEDICAL DOCUMENTATION; OVARY CANCER; PATIENT SATISFACTION; PERITONEUM CANCER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; TREATMENT WITHDRAWAL; UTERINE TUBE CARCINOMA;

EID: 1942508939     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.01.035     Document Type: Article

References (18)

1. Covens A., Carey M., Bryson P., Verma S., Fung Kee Fung M., Johnston M. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol. Oncol. 85:2002;71-80.
2. Markman M., Bookman M.A. Second-line treatment of ovarian cancer. Oncologist. 5:2000;26-35.
3. Lakusta C.M., Atkinson M.J., Robinson J.W., Nation J., Taenzer P.A., Campo M.G. Quality of life in ovarian cancer patients receiving chemotherapy. Gynecol. Oncol. 81:2001;490-495.
4. Hatch K.D., Beecham J.B., Blessing J.A., Creasman W.T. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer. 68:1991;269-271.
5. Cannistra S.A. Cancer of the ovary. N. Engl. J. Med. 329:1993;1550-1559.
6. Eisenhauer E.A., Vermorken J.B., van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann. Oncol. 8:1997;963-968.
7. Hoskins P.J., O'Reilly S.E., Swenerton K.D. The 'failure free interval' defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing. Int. J. Gynecol. Cancer. 1:1991;205-208.
8. Gore M.E., Fryatt I., Wiltshaw E., Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. 36:1990;207-211.
9. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S.et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9:1991;389-393.
10. Osborne C.K. Drug therapy. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 339:1998;1609-1618.
11. Marth C., Sorheim N., Kaern J., Trope C. Tamoxifen in the treatment of recurrent ovarian carcinoma. Int. J. Gynecol. Cancer. 7:1997;256-261.
12. Ahlgren J.D., Ellison N.M., Gottlieb R.J., Laluna F., Lokich J.J., Sinclair P.R.et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J. Clin. Oncol. 11:1993;1957-1968.
13. Markman M., Iseminger K.A., Hatch K.D., Creasman W.T., Barnes W., Dubeshter B. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group ancillary report. Gynecol. Oncol. 62:1996;4-6.
14. Williams C.J. Tamoxifen in relapsed ovarian cancer: a systematic review. Int. J. Gynecol. Cancer. 8:1998;89-94.
15. Van Der Velden J., Gitsch G., Wain G.V., Friedlander M.L., Hacker N.F. Tamoxifen in patients with advanced epithelial ovarian cancer. Int. J. Gynecol. Cancer. 5:1995;301-305.
16. Weiner S.A., Alberts D.S., Surwit E.A., Davis J., Grosso D. Tamoxifen therapy in recurrent epithelial ovarian carcinoma. Gynecol. Oncol. 27:1987;208-213.
17. Perez-Gracia J.L., Carrasco E.M. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol. Oncol. 84:2002;201-209.
18. Markman M. Follow-up of the asymptomatic patient with ovarian cancer. Gynecol. Oncol. 55:1994;S134-S137.